Medical Services (CE) (USOTC:MSITF)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Medical Services (CE) Charts. Click Here for more Medical Services (CE) Charts.](/p.php?pid=staticchart&s=NO%5EMSITF&p=8&t=15)
EDMONTON, Alberta, April 20 /PRNewswire-FirstCall/ -- Medical Services International Inc (Pinksheets: MSITF) wishes to announce that it projects that it will sell in excess of 5.3 VScan rapid test kits in the next fiscal year.
This projection is based on existing orders, orders currently being negotiated and the number of kits that distributors must purchase in order to maintain their distributorships.
Based on pricing that has been negotiated with distributors for the next year, tenders that have been submitted and working with government officials on pricing the Company is projecting sales in excess of $10,000,000 in gross revenues. This does not include the new products that the company is bringing on line in September 2007 or the fact that the company is adding new distributors weekly.
The projected breakdown of kits to be sold is 3,800,000 HIV, 700,000 Tuberculosis (TB) 500,000 Hepatitis C, 250,000 malaria, 50,000 miscellaneous other VScan kits.
About VScan
The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria and Prostate Cancer. The kits cannot be sold in Canada.
Medical Services International Inc trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/.
NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
DATASOURCE: Medical Services International Inc.
CONTACT: Robert Talbot of Medical Services International Inc.,
+1-780-430-6363
Web site: http://www.medicalservicesintl.com/
http://www.minerva-biotech.com/